Sarepta Therapeutics (SRPT) Scheduled to Post Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) will be announcing its earnings results after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.50. The firm had revenue of $396.80 million for the quarter, compared to analyst estimates of $387.18 million. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The business’s quarterly revenue was up 53.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.24) EPS. On average, analysts expect Sarepta Therapeutics to post $2 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded up $3.87 during trading on Thursday, reaching $128.12. 400,903 shares of the company traded hands, compared to its average volume of 976,503. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $159.89. The firm has a market capitalization of $12.03 billion, a PE ratio of -20.61 and a beta of 0.94. The company’s 50 day moving average is $126.18 and its two-hundred day moving average is $110.31.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on SRPT shares. Wedbush reissued an “outperform” rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. BMO Capital Markets began coverage on Sarepta Therapeutics in a research note on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price target on the stock. UBS Group increased their price target on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a report on Friday, March 1st. Needham & Company LLC decreased their price target on Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. Finally, Mizuho lifted their price target on Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $158.38.

Insider Activity

In other news, Director Kathryn Jean Boor sold 761 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now owns 7,516 shares of the company’s stock, valued at $923,941.88. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the sale, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Ian Michael Estepan sold 1,200 shares of Sarepta Therapeutics stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the completion of the sale, the chief financial officer now directly owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The disclosure for this sale can be found here. Insiders sold 22,096 shares of company stock worth $2,739,419 over the last quarter. 7.40% of the stock is currently owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.